var data={"title":"Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/contributors\" class=\"contributor contributor_credentials\">Denise Adams, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/contributors\" class=\"contributor contributor_credentials\">Ilona J Frieden, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 29, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H357895344\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tufted angioma and kaposiform hemangioendothelioma (KHE) are rare vascular tumors that typically occur during infancy or early childhood. Tufted angioma, previously known as &quot;angioblastoma of Nakagawa,&quot; is a benign tumor whose name derives from its histopathologic appearance characterized by tufts of capillaries within the dermis [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/1,2\" class=\"abstract_t\">1,2</a>]. KHE is a locally aggressive tumor that may involve superficial and deep soft tissues and, rarely, the retroperitoneum, mediastinum, and internal organs [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3,4\" class=\"abstract_t\">3,4</a>]. </p><p>Tufted angioma and KHE share several histopathologic and clinical features and are thought to be part of the same neoplastic spectrum [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/5,6\" class=\"abstract_t\">5,6</a>]. The most serious complication of these tumors is the Kasabach-Merritt phenomenon, a life-threatening coagulopathy characterized by severe thrombocytopenia and consumption of fibrinogen and other coagulation factors [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Tufted angioma, KHE, and the Kasabach-Merritt phenomenon will be discussed in this topic. Infantile hemangiomas, congenital hemangiomas, venous malformations, capillary malformations and associated syndromes, and Klippel-Trenaunay syndrome are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=infantile-hemangiomas-evaluation-and-diagnosis\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Evaluation and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=infantile-hemangiomas-management\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Management&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=rapidly-involuting-congenital-hemangioma-rich-and-noninvoluting-congenital-hemangioma-nich\" class=\"medical medical_review\">&quot;Rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=venous-malformations\" class=\"medical medical_review\">&quot;Venous malformations&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H357895351\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tufted angioma and kaposiform hemangioendothelioma (KHE) are rare [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Their exact incidence is unknown. Based upon the cases observed at a large referral center, the incidence of KHE has been estimated at 0.<span class=\"nowrap\">07/100,000</span> children per year [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Both sexes are affected equally. Approximately 50 percent of cases are present at birth; the remainder develops after the neonatal period, most often in the first year of life. However, later onset during childhood and even in adulthood has been reported [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/10\" class=\"abstract_t\">10</a>]. The Kasabach-Merritt phenomenon occurs in approximately 70 percent of cases of KHE and 10 percent of tufted angiomas [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3,11\" class=\"abstract_t\">3,11</a>]. </p><p class=\"headingAnchor\" id=\"H357895358\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of tufted angioma and kaposiform hemangioendothelioma (KHE) is poorly understood. The neoplastic spindle cells of KHE express the vascular markers CD31 and CD34, the vascular endothelial growth factor receptor-3 (VEGFR-3), a receptor required for lymphangiogenesis, and the lymphatic markers D2-40, and PROX1 [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/4,5,12-14\" class=\"abstract_t\">4,5,12-14</a>]. These findings suggest that KHE may derive from the lymphatic endothelium, similarly to Kaposi sarcoma. However, in contrast with Kaposi sarcoma, human herpesvirus 8 (HHV8) transcripts have not been identified in KHE and there is no evidence of association with HHV8 infection [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/12\" class=\"abstract_t\">12</a>]. </p><p class=\"headingAnchor\" id=\"H1841338\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tufted angioma is characterized by multiple, discrete lobules of tightly packed capillaries (tufts) scattered in the dermis and sometimes in the subcutis in a so-called &quot;cannonball&quot; pattern (<a href=\"image.htm?imageKey=DERM%2F89833\" class=\"graphic graphic_picture graphicRef89833 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/15\" class=\"abstract_t\">15</a>]. These capillary tufts are surrounded by cleft-like, semilunar empty vascular spaces. Thin-walled lymphatic spaces may be seen throughout the dermis. Mitoses are rare.</p><p>In KHE, there are areas of fibrosis with dilated thin-walled vessels surrounded by coalescing lobules or sheets of tightly packed spindle cells with an infiltrative pattern in the dermis, subcutaneous fat, and muscles (<a href=\"image.htm?imageKey=DERM%2F89834\" class=\"graphic graphic_picture graphicRef89834 \">picture 2</a>). Slit-like lumina reminiscent of Kaposi sarcoma may be seen. Mixed with these areas are nests of rounded epithelioid cells of vascular origin and aggregates of capillaries with round or irregularly shaped lumens containing platelet-rich fibrin thrombi. There is usually the presence of abnormal lymphatic spaces either within or at the periphery of the lesion. The rate of mitosis is variable but usually low.</p><p>Immunohistochemical studies reveal that the endothelial cells express the vascular markers CD31 and CD34 and the vascular endothelial growth factor receptor-3 (VEGFR-3), a marker of lymphangiogenesis, in both tufted angioma and KHE. The lymphatic markers D2-40 and PROX1 are also positive, supporting the concept of &quot;lymphothelial&quot; tumors arising from the lymphatic endothelium [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/4,5,12,13\" class=\"abstract_t\">4,5,12,13</a>].</p><p>The significant morphologic overlap between tufted angioma and KHE suggests that they may be part of a continuum, in which superficial cutaneous lesions show the classical findings of tufted angioma, whereas lesions infiltrating the subcutaneous tissues or involving visceral sites have the features of KHE [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/6,16,17\" class=\"abstract_t\">6,16,17</a>]. </p><p class=\"headingAnchor\" id=\"H357895365\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H357895374\"><span class=\"h2\">Tufted angioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tufted angiomas usually present as infiltrated, firm, dusky red to violaceous plaques or nodules with ill-defined borders (<a href=\"image.htm?imageKey=DERM%2F89065\" class=\"graphic graphic_picture graphicRef89065 \">picture 3E</a>). The size varies from less than 1 cm to more than 10 cm (<a href=\"image.htm?imageKey=DERM%2F89065\" class=\"graphic graphic_picture graphicRef89065 \">picture 3E</a>). Lesions are typically located on the arms, legs, and trunk. In contrast with infantile hemangiomas, cranial and facial lesions are uncommon. Lanugo hair hypertrichosis and increased sweating in the area overlaying the tumor also have been described [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Tufted angioma typically manifests during infancy or early childhood, but cases with onset in adult life have been reported [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/10,19,20\" class=\"abstract_t\">10,19,20</a>]. At birth, lesions are either absent or barely evident as a faint pink or brown discoloration. Over time, the tumor thickens into a plaque, often becoming dusky red or violaceous in color (<a href=\"image.htm?imageKey=DERM%2F89065\" class=\"graphic graphic_picture graphicRef89065 \">picture 3E</a>); some develop distinct nodularity or focal papules. Eventually, lesions stabilize in size and tend to persist unchanged. However, partial or complete regression during infancy or childhood has been reported in a few cases [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p>Tufted angiomas are usually solitary but multifocal or disseminated disease has been reported [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/23\" class=\"abstract_t\">23</a>]. A rare eruptive form has been described in immunosuppressed patients [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/24\" class=\"abstract_t\">24</a>]. Approximately 10 percent of tufted angiomas develop the Kasabach-Merritt phenomenon [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H357895395\" class=\"local\">'Kasabach-Merritt phenomenon'</a> below.)</p><p class=\"headingAnchor\" id=\"H357895381\"><span class=\"h2\">Kaposiform hemangioendothelioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Kaposiform hemangioendothelioma (KHE)<strong> </strong>may be present at birth or develop in early childhood. It appears as a slightly raised subcutaneous mass with a purpuric, bruised appearance and occasional telangiectasias (<a href=\"image.htm?imageKey=DERM%2F89343%7EDERM%2F89260\" class=\"graphic graphic_picture graphicRef89343 graphicRef89260 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/7,25,26\" class=\"abstract_t\">7,25,26</a>]. Increased hair growth or sweating overlying the tumor may be evident. </p><p>In most cases, the tumor involves the extremities; less frequent locations include the trunk and the cervicofacial region [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3\" class=\"abstract_t\">3</a>]. Approximately 10 percent of KHE do not involve the skin. The retroperitoneum is the most frequent extracutaneous location, followed by muscle, bone, and thoracic cavity. Deep retroperitoneal lesions or intrathoracic lesions can cause a bluish-purpuric hue on the skin and may be mistaken for a bleeding problem. </p><p>Over time, especially in cases associated with severe coagulopathy, the tumor becomes indurated and firm with a red-purple hue, ecchymoses, and petechiae (<a href=\"image.htm?imageKey=DERM%2F89100%7EDERM%2F89343\" class=\"graphic graphic_picture graphicRef89100 graphicRef89343 \">picture 3A, 3C</a>). In some cases, the appearance of these lesions can be dramatic, with massive involvement of an entire extremity or other body parts. As the tumor grows, it infiltrates surrounding tissue planes (<a href=\"image.htm?imageKey=DERM%2F89264\" class=\"graphic graphic_picture graphicRef89264 \">picture 3D</a>). </p><p>Over 70 percent of KHE develop the Kasabach-Merritt phenomenon (KMP) [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3\" class=\"abstract_t\">3</a>]. The risk is highest for large, congenital lesions and lesions located in the retroperitoneum or mediastinum. (See <a href=\"#H357895395\" class=\"local\">'Kasabach-Merritt phenomenon'</a> below.)</p><p>Tumors without KMP usually occur in toddler or older children and are relatively small (&lt;8 cm in diameter) [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/27\" class=\"abstract_t\">27</a>]. They appear as firm soft tissue masses that can be indurated, light brown, violaceous, or erythematous in color, without purpura or petechiae. These tumors can cause pain or functional impairment depending on the area of involvement [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H357895395\"><span class=\"h2\">Kasabach-Merritt phenomenon</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Kasabach-Merritt phenomenon (KMP) is a life-threatening complication occurring in approximately 70 percent of cases of kaposiform hemangioendothelioma (KHE) and 10 percent of tufted angioma [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3,11\" class=\"abstract_t\">3,11</a>]. KMP is characterized by profound thrombocytopenia and consumption coagulopathy. Since its first description in an infant with a &quot;giant capillary hemangioma,&quot; the term has been used indiscriminately to describe thrombocytopenia or coagulopathy associated with any vascular anomaly [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/7\" class=\"abstract_t\">7</a>]. However, it is now clear that KMP is a complication of tufted angioma and KHE, and not of infantile or congenital hemangiomas [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/7,26\" class=\"abstract_t\">7,26</a>]. These tumors can cause pain or functional impairment depending on the area of involvement [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Why KMP develops exclusively in the setting of tufted angioma or KHE is unclear. One hypothesis is that the abnormal endothelium and convoluted architecture of the tumor vasculature promote platelet adhesion and trapping [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/12\" class=\"abstract_t\">12</a>]. Platelet aggregation and activation result in thrombocytopenia, consumption of fibrinogen, and ongoing fibrinolysis, leading to intralesional bleeding and tumor enlargement [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/8\" class=\"abstract_t\">8</a>]. </p><p>The presenting sign of KMP is a rapid enlargement of the tumor, which becomes tense, purpuric or ecchymotic, and painful (<a href=\"image.htm?imageKey=DERM%2F89100%7EDERM%2F89264\" class=\"graphic graphic_picture graphicRef89100 graphicRef89264 \">picture 3C-D</a>). These changes are accompanied by a rapid drop in the platelet count. The thrombocytopenia ranges from 3000 to <span class=\"nowrap\">60,000/microL</span>. Fibrinogen levels are usually less than 1 <span class=\"nowrap\">g/L;</span> D-dimer and fibrin degradation products are elevated. The prothrombin time and the activated partial thromboplastin time are usually normal or minimally elevated. </p><p>Severe anemia caused by sequestration of red blood cells in the tumor also may occur. Occasionally, microangiopathic hemolytic anemia can be seen on the blood smear. (See <a href=\"topic.htm?path=approach-to-the-patient-with-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma\" class=\"medical medical_review\">&quot;Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)&quot;</a>.)</p><p>Despite the profound thrombocytopenia, severe hemorrhage is rare. However, trauma (eg, biopsy, surgical procedure), ulceration, infection, or delay in initiating treatment may induce progression to a more systemic coagulopathy similar to disseminated intravascular coagulation [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/25\" class=\"abstract_t\">25</a>]. </p><p class=\"headingAnchor\" id=\"H357895402\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of tufted angioma and kaposiform hemangioendothelioma (KHE) is based upon the combination of clinical, histologic, and imaging features. Laboratory evaluation is essential for the diagnosis of Kasabach-Merritt phenomenon (KMP). </p><p class=\"headingAnchor\" id=\"H26920701\"><span class=\"h2\">Clinical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of tufted angioma or KHE is suspected in an infant presenting with an atypical indurated vascular lesion, red to purple in color, with ill-defined borders, most often located on the extremities or trunk (<a href=\"image.htm?imageKey=DERM%2F89065%7EDERM%2F89100%7EDERM%2F89264%7EDERM%2F89343\" class=\"graphic graphic_picture graphicRef89065 graphicRef89100 graphicRef89264 graphicRef89343 \">picture 3A, 3C-E</a>). The presence of hypertrichosis <span class=\"nowrap\">and/or</span> hyperhidrosis overlying the lesion is a clue to the diagnosis. (See <a href=\"#H357895374\" class=\"local\">'Tufted angioma'</a> above and <a href=\"#H357895381\" class=\"local\">'Kaposiform hemangioendothelioma'</a> above.) </p><p class=\"headingAnchor\" id=\"H26920734\"><span class=\"h2\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whenever possible, histologic confirmation of the diagnosis of tufted angioma or KHE should be considered, since therapy is often needed for a prolonged period of time.&nbsp;However, the presence of a highly vascular tumor together with thrombocytopenia and coagulopathy greatly increases the risk of a biopsy.&nbsp;If clinical and imaging findings are highly suggestive of the diagnosis, deferring biopsy is an option. If a decision to biopsy is made, the plan needs to be discussed with the surgeon, anesthesiologist,&nbsp;hematologist, and pathologist involved.&nbsp;The biopsy should be performed in the operating room; supportive care with platelet transfusions, fresh frozen plasma, and other products may be needed pre- and postoperatively and during the procedure. </p><p>The diagnosis of tufted angioma is confirmed by the finding of discrete lobules (tufts) of tightly packed capillaries scattered in the dermis in a so-called &quot;cannonball pattern.&quot; The finding of lobules or sheets of tightly packed spindled or more rounded endothelial cells, with an infiltrative pattern in the dermis, subcutaneous fat, and muscles is diagnostic of KHE. On immunohistochemistry, staining for the lymphatic markers D2-40 and PROX1 are positive in tufted angioma and KHE, whereas GLUT-1, the marker for infantile hemangiomas, is always negative. (See <a href=\"#H1841338\" class=\"local\">'Histopathology'</a> above.)</p><p class=\"headingAnchor\" id=\"H1841272\"><span class=\"h2\">Laboratory evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory evaluation of tufted angioma and KHE includes a complete blood count with platelet count, D-dimer, fibrinogen, prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR). Liver and renal function tests should be performed in acutely ill patients. </p><p>The detection of severe thrombocytopenia, hypofibrinogenemia, and elevated D-dimer suggests the diagnosis of KMP. However, other rare tumors of infancy (eg, congenital hemangiomas, hemangiopericytoma, infantile fibrosarcoma, angiosarcoma) and venous malformations may be associated with thrombocytopenia and coagulopathy. (See <a href=\"#H357895423\" class=\"local\">'Differential diagnosis'</a> below.) </p><p class=\"headingAnchor\" id=\"H357895409\"><span class=\"h2\">Imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Magnetic resonance imaging (MRI) is helpful in differentiating tufted angioma and KHE from other tumors, but its main utility is to delineate the extent of disease and document the response to treatment, particularly in cases with extracutaneous involvement. T1 weighted sequences typically show a poorly circumscribed soft tissue mass with soft tissue and dermal thickening and diffuse enhancement with gadolinium. T2 weighted sequences show a diffuse increased signal with stranding in the subcutaneous fat [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/27\" class=\"abstract_t\">27</a>]. Gradient sequences show mildly dilated vessels in and around the soft tissue mass. </p><p class=\"headingAnchor\" id=\"H357895423\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of tufted angioma and kaposiform hemangioendothelioma (KHE) includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infantile hemangiomas</strong> &ndash; Infantile hemangiomas are not completely formed at birth, are more commonly located in the head and neck area, and have a predilection for females (<a href=\"image.htm?imageKey=PEDS%2F60004%7EPEDS%2F50388\" class=\"graphic graphic_picture graphicRef60004 graphicRef50388 \">picture 4A-B</a>). They are <strong>not</strong> associated with a coagulopathy. On histology, they exhibit lobulated masses of proliferating endothelial cells and strong expression of GLUT-1. (See <a href=\"topic.htm?path=infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Congenital hemangiomas</strong> &ndash; Congenital hemangiomas are vascular tumors that are fully formed at birth. Rapidly involuting congenital hemangiomas (RICH) can cause platelet trapping with mild thrombocytopenia and hypofibrinogenemia that resolve spontaneously over a few weeks. Clinically, RICH can be quite difficult to distinguish from those KHE (a minority) that present as tumors at birth. Histologically, RICH differ in having lobules of capillary proliferations embedded in a fibrous stroma without spindle cell or lymphatic ectasias. (See <a href=\"topic.htm?path=rapidly-involuting-congenital-hemangioma-rich-and-noninvoluting-congenital-hemangioma-nich\" class=\"medical medical_review\">&quot;Rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH)&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Kaposiform lymphangiomatosis </strong>&ndash; Kaposiform lymphangiomatosis (KLA) is a new entity classified under the heading of lymphatic anomaly that is distinct from generalized lymphatic anomaly (GLA) and KHE in its histology, clinical course, and outcome [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/29\" class=\"abstract_t\">29</a>]. Histologically, KLA is characterized by diffuse lymphatic malformation with focal areas of &quot;kaposiform&quot; spindle cells versus the diffuse nature of the spindle cells in KHE. Clinically, KLA can be multifocal or diffuse throughout the lung <span class=\"nowrap\">and/or</span> abdomen. Other organ involvement can occur, including soft tissue, bone, spleen, liver, and brain. The disorder is associated with hemorrhagic pleural effusions <span class=\"nowrap\">and/or</span> ascites. Patients can have mild to severe coagulopathy similar to KHE, including thrombocytopenia and hypofibrinogenemia. <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">Vincristine</a>, steroids, and <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> have all been used for treatment; however, the mortality is high despite aggressive therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/29-32\" class=\"abstract_t\">29-32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infantile hemangiopericytoma</strong> &ndash; Infantile hemangiopericytoma is now categorized as a form of infantile myofibromatosis [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/33-35\" class=\"abstract_t\">33-35</a>]. It is a rare soft tissue tumor that can contain two different clinical entities, the adult type and the infantile type, with the latter occurring in the first year of life [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/36\" class=\"abstract_t\">36</a>]. In newborns and infants the tumor may present as a multilobulated mass in the subcutis (<a href=\"image.htm?imageKey=DERM%2F89197\" class=\"graphic graphic_picture graphicRef89197 \">picture 5</a>). Consumption coagulopathy and bleeding may occur and mimic the Kasabach-Merritt phenomenon. Histology reveals well-circumscribed nodules of round-shaped and spindle-shaped cells with variable cytologic atypia and haphazard perivascular orientation and an increased number of thin-walled, branching &quot;staghorn&quot; vessels. (See <a href=\"topic.htm?path=skin-nodules-in-newborns-and-infants#H10\" class=\"medical medical_review\">&quot;Skin nodules in newborns and infants&quot;, section on 'Infantile myofibromatosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infantile fibrosarcoma</strong> &ndash; Infantile fibrosarcoma is a rare malignant tumor that can be present at birth or develop in the first years of life. Lesions present as rounded, firm tumors fixed to the deep tissue planes [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/37\" class=\"abstract_t\">37</a>]. Congenital lesions may mimic kaposiform hemangioendothelioma, particularly when associated with thrombocytopenia and coagulopathy. Histology is required for a precise diagnosis. (See <a href=\"topic.htm?path=skin-nodules-in-newborns-and-infants#H14\" class=\"medical medical_review\">&quot;Skin nodules in newborns and infants&quot;, section on 'Infantile fibrosarcoma'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Angiosarcomas</strong> &ndash;<strong> </strong>Angiosarcomas are extremely rare in children, but cases have been reported in neonates and toddlers, with presentation of multiple cutaneous lesions and liver lesions, some of which are <em>GLUT1</em>-positive [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/16-19,38\" class=\"abstract_t\">16-19,38</a>]. Large lesions and multiple lesions have been associated with coagulopathy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Venous malformations</strong> &ndash; Venous malformations are slow-flow vascular malformations that usually present at birth as soft, compressible blue masses that enlarge when the affected area is in a dependent position or with physical activity or crying. Venous malformations can be multifocal or diffuse. Imaging studies, including Doppler ultrasonography and magnetic resonance imaging, are helpful in distinguishing venous malformations from vascular tumors [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/39\" class=\"abstract_t\">39</a>]. In extensive venous malformations (multifocal or diffuse), localized intravascular clotting results in consumption coagulopathy, with elevated D-dimers and low fibrinogen. However, in contrast with the Kasabach-Merritt phenomenon, thrombocytopenia is mild, with platelet counts rarely lower than 50,000 to <span class=\"nowrap\">60,000/microL</span>. (See <a href=\"topic.htm?path=venous-malformations\" class=\"medical medical_review\">&quot;Venous malformations&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Kaposi sarcoma </strong>&ndash; Kaposi sarcoma is exceedingly rare in children out of Africa. Histologically, Kaposi sarcoma presents extensive vascular proliferation in the dermis with multiple dilated vascular spaces and solid cords and fascicles of spindle cells arranged between the jagged vascular channels. The viral genome of human herpesvirus 8 (HHV8) is detectable in Kaposi sarcoma lesions at all stages, regardless of the clinical variant [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Coagulopathy is not common in these lesions. (See <a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment&quot;</a> and <a href=\"topic.htm?path=aids-related-kaposi-sarcoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis&quot;</a>.) </p><p/><p class=\"headingAnchor\" id=\"H357895430\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Guidelines for the management of complicated kaposiform hemangioendothelioma (KHE) have been proposed by an American and Canadian multidisciplinary expert panel, based upon a review of the available evidence, expert opinion, and clinical experience [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42\" class=\"abstract_t\">42</a>]. However, the approach to treatment must be individualized, based upon the size, location, presence of symptoms such as tenderness or functional compromise, and presence or absence of thrombocytopenia and coagulopathy. </p><p class=\"headingAnchor\" id=\"H55701629\"><span class=\"h2\">Patients without Kasabach-Merritt phenomenon</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several forms of treatment have been proposed for tufted angioma and KHE that are not complicated by the Kasabach-Merritt phenomenon (KMP). They include surgical excision, pulsed dye laser (for superficial, stain-like tumors), and multiple chemotherapy regimens using single or multiple agents. However, the efficacy of the various treatment modalities has not been evaluated in randomized trials or large observational studies. Limited evidence is based upon small case series, single case reports, and clinical experience. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For tumors of any size that are asymptomatic, do not involve vital organs, do not cause functional compromise, and are not disfiguring, observation may be an option. Spontaneous regression of tufted angioma during infancy or early childhood has been reported in a few patients [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/21,43-45\" class=\"abstract_t\">21,43-45</a>]. In a series of five patients with kaposiform hemangioendothelioma without KMP who did not receive any treatment, two tumors regressed spontaneously within two years and three remained stable after a follow-up time of 15 months to 6.5 years [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who are symptomatic or desire definitive treatment, surgical excision is the treatment of choice [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/18,45\" class=\"abstract_t\">18,45</a>]. However, since the tumor margins are often poorly defined, complete surgical excision may not be possible and medical management has been used with good results [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28\" class=\"abstract_t\">28</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For tumors that are not resectable, are symptomatic, and have a high risk of functional compromise, there is no consensus on the pharmacologic approach. For tufted angioma, we suggest <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> 5 <span class=\"nowrap\">mg/kg</span> per day as first-line therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/46\" class=\"abstract_t\">46</a>]. For KHE, in accord with an expert consensus panel, we suggest oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> or <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> 2 <span class=\"nowrap\">mg/kg</span> per day as first-line therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42\" class=\"abstract_t\">42</a>]. Aspirin at an antiplatelet dose of 2 to 5 <span class=\"nowrap\">mg/kg</span> per day can be given as an adjunctive therapy. Other treatments that have been used alone or in combination include <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a>, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>, interferon-alpha, and <a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a> [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/27,46-50\" class=\"abstract_t\">27,46-50</a>]. However, no single regimen has been studied in comparative prospective trials, and information on long-term outcomes and complete resolution of the tumor is lacking. </p><p/><p class=\"headingAnchor\" id=\"H357895437\"><span class=\"h2\">Patients with Kasabach-Merritt phenomenon</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of infants with tufted angioma or KHE and associated Kasabach-Merritt phenomenon (KMP) involves primarily the treatment of the tumor responsible for the coagulopathy and supportive measures to maintain hemostasis. </p><p class=\"headingAnchor\" id=\"H357895446\"><span class=\"h3\">Hemostasis support</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although platelet counts in KMP can be alarmingly low (eg, 3000 to <span class=\"nowrap\">5000/microL),</span> clinicians should not treat &quot;the numbers&quot; but &quot;the patient&quot; [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/9\" class=\"abstract_t\">9</a>]. Despite the profound thrombocytopenia, life-threatening hemorrhages are rare. However, severe bleeding can occur in patients with visceral involvement or disseminated intravascular coagulation and in those who have multiorgan failure [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/51\" class=\"abstract_t\">51</a>]. </p><p>Platelets should <strong>not</strong> be given unless the patient is actively bleeding or in preparation for surgery, because infused platelets have a short circulatory time and may induce a rapid increase in size of the tumor. In patients undergoing surgical procedures, platelets should be infused during the procedure. The half-life of platelets in this setting ranges between 1 and 24 hours. Several clinicians, including the authors, have observed rapid expansion of the lesion and increased pain following platelet infusions, probably secondary to clotting in the small vessels of the tumor. </p><p>Cryoprecipitate for the correction of hypofibrinogenemia should be given with careful consideration in the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Active bleeding </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Before surgical procedures</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Platelet count <span class=\"nowrap\">&lt;10,000/microL</span> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrinogen &lt;1 <span class=\"nowrap\">g/dL</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To stabilize the endothelium in critical infants with multiorgan system failure</p><p/><p>In case of active bleeding, <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-drug-information\" class=\"drug drug_general\">recombinant human factor VIIa</a> can be used at a dose of 90 <span class=\"nowrap\">mcg/kg</span> [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/52\" class=\"abstract_t\">52</a>]. Infants with disseminated intravascular coagulation and prolonged PT and aPTT may need the replacement of the other coagulation factors with fresh frozen plasma (see <a href=\"topic.htm?path=disseminated-intravascular-coagulation-in-infants-and-children\" class=\"medical medical_review\">&quot;Disseminated intravascular coagulation in infants and children&quot;</a>). Despite abnormal coagulation parameters that sometimes include abnormal PT, aPTT, and INR, heparin and low molecular-weight heparin should not be used in the management of KMP. </p><p>Transfusion of packed red blood cells should be given if the patient has symptomatic anemia. (See <a href=\"topic.htm?path=red-blood-cell-transfusion-in-infants-and-children-selection-of-blood-products\" class=\"medical medical_review\">&quot;Red blood cell transfusion in infants and children: Selection of blood products&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H357895453\"><span class=\"h3\">Surgical treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tufted angiomas and KHE associated with the Kasabach-Merritt phenomenon are usually large and infiltrative lesions that do not allow a complete surgical excision. However, for small or localized tumors or tumors whose size has been reduced by pharmacologic therapy, surgical excision is a treatment option [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/53-55\" class=\"abstract_t\">53-55</a>]. Surgical excision may be a second-line approach for tumors that have failed medical management or for imminently life-threatening tumors when the time to response to medical therapy is considered too long [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42\" class=\"abstract_t\">42</a>]. </p><p class=\"headingAnchor\" id=\"H357895474\"><span class=\"h3\">Pharmacologic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In symptomatic or high-risk (KMP) tufted angiomas or KHE, pharmacologic therapy should be initiated to improve abnormal hematologic parameters, improve symptoms, and decrease the tumor mass. Chemotherapy agents that have been used for the treatment of these tumors include systemic corticosteroids, <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a>, the mTOR inhibitor <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, and interferon-alpha. At present, it has not been established which agent or combination of agents is optimal [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/8,9,56\" class=\"abstract_t\">8,9,56</a>]. In many cases, multiple agents are given in sequence or in combination. </p><p>In 2013, an expert panel recommended steroids and <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> as first-line treatment for <span class=\"nowrap\">KHE/KMP</span> [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42\" class=\"abstract_t\">42</a>]. However, subsequent case reports, case series, and a prospective clinical trial have shown very encouraging results with the mTOR inhibitor <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, suggesting that it may be considered an alternative first-line therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28,48,57-64\" class=\"abstract_t\">28,48,57-64</a>]. A prospective study comparing vincristine with sirolimus in high-risk KHE patients is open and enrolling at eight sites in the United States (<a href=\"https://clinicaltrials.gov/ct2/show/NCT02110069?term=sirolimus+vincristine+hemangioendothelioma&rank=1&amp;token=kTQy2WSlRRqJASksLjG68OutliMl7/6vThapsQjxLtPsc0B0hbfp/ion7aCgAnH4+upYSLGY1X/B2DvHnDRZZM/Gk58osFVdrTzbyUrDqKBDgm1PM2icL2psNvXfDMSuRk3+zcJV4B8c4u3NEZJf3Q==&amp;TOPIC_ID=86314\" target=\"_blank\" class=\"external\">NCT02110069</a>). (See <a href=\"#H333840970\" class=\"local\">'Sirolimus'</a> below.)</p><p class=\"headingAnchor\" id=\"H4473191\"><span class=\"h4\">Systemic corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>High-dose systemic corticosteroids are often used as a first-line therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/9,65,66\" class=\"abstract_t\">9,65,66</a>]. They are typically initiated at a dose of 2 to 3 <span class=\"nowrap\">mg/kg</span> per day. Stabilization of the platelet counts is usually observed in one to two days. Sustained response, however, is variable and most patients do not improve with steroids alone, even when higher doses (eg, 5 <span class=\"nowrap\">mg/kg)</span> or bolus doses of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> (eg, 30 <span class=\"nowrap\">mg/kg</span> per day for three days) are given [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/67-73\" class=\"abstract_t\">67-73</a>]. </p><p>If an increase in the platelet count is noted in one to two weeks, corticosteroids can be slowly tapered over the following four weeks. If there is no response or a relapse of thrombocytopenia occurs when tapering the corticosteroids, treatment with a second agent (eg, <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a>, interferon-alpha, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>) is recommended. </p><p class=\"headingAnchor\" id=\"H4473187\"><span class=\"h4\">Vincristine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">Vincristine</a>, a chemotherapy agent that promotes endothelial apoptosis, has emerged as a first-line or early second-line therapy in combination with a tapering dose of systemic corticosteroids [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/74\" class=\"abstract_t\">74</a>]. Vincristine is given at a weekly dose of 0.025 to 0.05 <span class=\"nowrap\">mg/kg</span> for infants &lt;10 kg and 1.0 to 1.5 <span class=\"nowrap\">mg/m<sup>2</span> </sup>for infants &gt;10 kg for two months [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42,75\" class=\"abstract_t\">42,75</a>]. </p><p>If a response is noted (hematologic response, complete regression, or reduction in size of the tumor), the administration interval can be increased to every two weeks for two months and then to every three weeks for two months. In one case series, the average time to platelet increase was two months and average time to decrease in tumor size was four months [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/74\" class=\"abstract_t\">74</a>]. </p><p>In a small number of patients, <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> has been used in combination with antiplatelet agents [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/76-78\" class=\"abstract_t\">76-78</a>]. In a retrospective study, 11 children aged 0 to 36 months were treated with vincristine 0.05 <span class=\"nowrap\">mg/kg</span> weekly for four months [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/78\" class=\"abstract_t\">78</a>]. <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> 10 <span class=\"nowrap\">mg/kg</span> per day, and <a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a> 10 <span class=\"nowrap\">mg/kg</span> per day were also given and continued for a total of 14 months. An increase in platelet count to 100,000 or more was observed in all children within three weeks of starting treatment. All patients were alive and clinically free of disease after a median follow-up of 4.5 years (range 2 to 17).</p><p><a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">Vincristine</a> is a vesicant and should be given through a central venous line. Adverse effects include peripheral polyneuropathy, loss of tendon reflexes, and abdominal autonomic dysfunction [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/74,78\" class=\"abstract_t\">74,78</a>]. </p><p class=\"headingAnchor\" id=\"H333840970\"><span class=\"h4\">Sirolimus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">Sirolimus</a>, an inhibitor of mammalian target of rapamycin, has been suggested as a treatment option for complicated vascular anomalies and tumors in children, including KHE and KMP [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28,48,57-60,79\" class=\"abstract_t\">28,48,57-60,79</a>]. A growing evidence from several case series and from a phase II trial of sirolimus in children with complicated vascular anomalies supports the efficacy of sirolimus as monotherapy or in combination with oral corticosteroids for cases refractory to previous therapies such as <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> and corticosteroids [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28,80-83\" class=\"abstract_t\">28,80-83</a>]. </p><p>Advantages of <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> include oral administration without the need for a central line and a more rapid resolution of coagulopathy (typically within one month of administration or sooner), compared with <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> and steroid combination. However, a concern raised in several reports is the phenomenon of &quot;relapse&quot; or worsening of clinical status after the medication is discontinued or during a &quot;weaning schedule.&quot; This can happen relatively quickly even after dramatic clinical response, raising the issue of whether longer-term maintenance therapy with sirolimus may be needed in some cases [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/83\" class=\"abstract_t\">83</a>].</p><p>In a phase II clinical trial evaluating the safety and efficacy of <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> for the treatment of complicated vascular anomalies in children (including, but not limited to, KHE), sirolimus induced a partial response (complete response of hematologic parameters with partial tumor response) in all patients with <span class=\"nowrap\">KHE/KMP</span> [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28\" class=\"abstract_t\">28</a>]. Sirolimus was given at the dose of 0.8 <span class=\"nowrap\">mg/m<sup>2</sup></span> twice daily, with careful monitoring and adjustment to keep serum levels between 10 to 15 <span class=\"nowrap\">ng/mL</span> using pharmacodynamic modeling. Patients also received supportive care, including <em>Pneumocystis </em>pneumonia prophylaxis. </p><p>Careful consideration is needed in dosing <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> in pediatric patients to achieve the target dose of approximately 10 to 15 <span class=\"nowrap\">ng/mL;</span> close monitoring of the serum levels should be performed, and dose adjustments should be made accordingly [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/84,85\" class=\"abstract_t\">84,85</a>]. The suggested dosing regimens are derived in part from the phase II prospective study (<a href=\"image.htm?imageKey=DERM%2F115485\" class=\"graphic graphic_table graphicRef115485 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28\" class=\"abstract_t\">28</a>]. Neonates and infants need a lower dosing regimen secondary to physiologic differences in drug metabolism [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/84,85\" class=\"abstract_t\">84,85</a>]. </p><p>Long-term data on the duration of response to <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, dosing regimens needed during maintenance treatment, and long-term toxicity are limited, but some results will be likely provided by an ongoing analysis of follow-up data from the phase II trial. A further phase II clinical trial (<a href=\"https://clinicaltrials.gov/ct2/show/NCT02110069&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH+MCpwZ1/1ekxPO9RfYNVuIE+cvXcSTZHNxk5rbnw97dgATVKsinHn4OQg==&amp;TOPIC_ID=86314\" target=\"_blank\" class=\"external\">NCT02110069</a>) comparing vincristine-based therapy with sirolimus for the treatment of high-risk <span class=\"nowrap\">KHE/KMP</span> patients is ongoing. </p><p class=\"headingAnchor\" id=\"H2081252668\"><span class=\"h4\">Interferon-alpha</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Interferon-alpha at dose of 3 <span class=\"nowrap\">MU/m<sup>2</span> </sup>per day has been used in a small number of infants with KMP, often in combination with other treatment modalities [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/9,86-95\" class=\"abstract_t\">9,86-95</a>]. The optimal duration of therapy has not been determined [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/9,86\" class=\"abstract_t\">9,86</a>].</p><p>The use of interferon-alpha in infants is limited by potentially serious neurologic adverse effects, including motor disturbances and spastic diplegia, which can be permanent [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/96\" class=\"abstract_t\">96</a>]. Interferon-alpha should not be used in infants under 12 months.</p><p class=\"headingAnchor\" id=\"H1655573282\"><span class=\"h4\">Multiagent chemotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiagent chemotherapy (eg, <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> and actinomycin, vincristine and <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>) has been used for the treatment of KMP with variable response [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/56,97-99\" class=\"abstract_t\">56,97-99</a>]. </p><p class=\"headingAnchor\" id=\"H2183472915\"><span class=\"h4\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antifibrinolytic agents (<a href=\"topic.htm?path=tranexamic-acid-drug-information\" class=\"drug drug_general\">tranexamic acid</a> and <a href=\"topic.htm?path=aminocaproic-acid-drug-information\" class=\"drug drug_general\">aminocaproic acid</a>) have been used in a few cases of KMP with mixed results [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/100-103\" class=\"abstract_t\">100-103</a>]. Antiplatelet agents (eg, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, <a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a>) are usually used in combination with other treatments such as systemic corticosteroids and <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/78\" class=\"abstract_t\">78</a>]. </p><p><a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">Propranolol</a> has been suggested as a possible treatment for tufted angioma and KHE, given its remarkable efficacy in the treatment of infantile hemangiomas. However, in a small case series of 11 patients, improvement was noted only in four [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/49\" class=\"abstract_t\">49</a>]. </p><p class=\"headingAnchor\" id=\"H1371846\"><span class=\"h3\">Embolization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with symptomatic or high-risk tumors, embolization may be helpful in decreasing the blood flow to the lesion before initiating a pharmacologic treatment [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/104-106\" class=\"abstract_t\">104-106</a>]. However, embolization may not be feasible in tumors that have multiple small feeding vessels. </p><p class=\"headingAnchor\" id=\"H1371853\"><span class=\"h3\">Radiation therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Low dose radiotherapy is rarely used for the treatment of KMP. Because of the risk of secondary malignancies, radiotherapy should be considered a last resort treatment for tumors that are unresponsive to other therapies [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/107-112\" class=\"abstract_t\">107-112</a>].</p><p class=\"headingAnchor\" id=\"H19597040\"><span class=\"h2\">Our approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest intravenous <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> plus systemic corticosteroids <strong>or</strong> oral <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> with or without systemic corticosteroids as first-line therapies for patients with KHE associated with KMP. Although evidence continues to emerge supporting the use of oral sirolimus as a first-line therapy for patients with complicated KHE with or without KMP, there are no specific criteria (based upon exact risk stratification) to determine which patients will benefit from sirolimus rather than vincristine. Areas of uncertainty include sirolimus dosing, optimal length of treatment for both vincristine and sirolimus, and long-term effects. </p><p>Intravenous <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> 0.05 <span class=\"nowrap\">mg/kg</span> is given intravenously once weekly. Oral <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> 2 <span class=\"nowrap\">mg/kg</span> or intravenous <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> 1.6 <span class=\"nowrap\">mg/kg</span> is given daily. The duration of therapy should be based upon each individual patient's response to treatment. The goal is to taper off the corticosteroids to zero over four to eight weeks if there has been good clinical response and stabilization of the patient's hematologic status. Vincristine is typically administered for 20 to 24 weeks, based upon the tumor response to treatment and acceptable therapy-related toxicity.</p><p><a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">Sirolimus</a> is typically given orally at the dose of 0.8 to 1 <span class=\"nowrap\">mg/m<sup>2</sup></span> per dose twice daily with close pharmacokinetic monitoring. Blood levels of sirolimus should not be higher than 10 to 13 <span class=\"nowrap\">ng/mL</span>. In newborns, lower doses are required with more frequent monitoring [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/84,86\" class=\"abstract_t\">84,86</a>]. Trough blood levels should be checked weekly, until stable at least twice in a row, and monthly thereafter. Levels should also be monitored with illness. Neonates and infants may need twice-weekly monitoring of trough levels initially. </p><p>Oral <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> can be given in combination with <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> at doses of 2 <span class=\"nowrap\">mg/kg</span> per day but should be weaned over one to two months. Several reports have noted a rapid response of hematologic parameters within one to two weeks of sirolimus therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28,57-59\" class=\"abstract_t\">28,57-59</a>]. We recommend the use of <em>Pneumocystis</em> pneumonia prophylaxis, especially in the neonatal and toddler age group. </p><p>Surgical excision may be a second-line approach for tumors that have failed medical management or for life-threatening tumors when the time to response to medical therapy is considered too long [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42\" class=\"abstract_t\">42</a>]. Embolization may be performed in conjunction with surgery to minimize bleeding during resection. In life-threatening situations, embolization alone may provide a temporary reduction in size of the tumor and allow more time for medical therapy to be effective. </p><p class=\"headingAnchor\" id=\"H357895481\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tufted angioma and kaposiform hemangioendothelioma (KHE) can undergo spontaneous or treatment-induced regression but never resolve completely [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/21,22\" class=\"abstract_t\">21,22</a>]. A study evaluating patients 10 years after their diagnosis found active tumor on radiologic imaging and repeat biopsy in most patients [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/17\" class=\"abstract_t\">17</a>].</p><p>In the past, a mortality rate of 12 to 24 percent has been reported among patients with the Kasabach-Merritt phenomenon; however, mortality rates have decreased over time due to improved pharmacologic therapy [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/25\" class=\"abstract_t\">25</a>]. The leading causes of death include hemorrhage, sepsis, organ failure, or invasion of vital structures. Hemorrhage is more common in retroperitoneal and intrapleural tumors [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/16,61,107\" class=\"abstract_t\">16,61,107</a>]. </p><p>The cutaneous outcome of tufted angioma and KHE includes three types of residual lesions: vascular stains with papules, soft tissue swelling with telangiectasias, and fibrotic subcutaneous infiltrate. Long-term complications that can significantly impair quality of life include lymphedema, recurrent inflammation, pain, and orthopedic issues (eg, contractures, scoliosis, impaired function) [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/113\" class=\"abstract_t\">113</a>]. Late complications often arise around puberty [<a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/114\" class=\"abstract_t\">114</a>].</p><p class=\"headingAnchor\" id=\"H357895488\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tufted angioma and kaposiform hemangioendothelioma (KHE) are rare vascular tumors that typically occur during infancy or early childhood. They may be associated with the Kasabach-Merritt phenomenon, a life-threatening complication characterized by severe thrombocytopenia and coagulopathy. (See <a href=\"#H357895344\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tufted angioma usually presents as infiltrated, firm, dusky red to violaceous plaques or nodules with ill-defined borders (<a href=\"image.htm?imageKey=DERM%2F89065\" class=\"graphic graphic_picture graphicRef89065 \">picture 3E</a>). KHE<strong> </strong>appears as a subcutaneous mass with a purpuric, bruised appearance (<a href=\"image.htm?imageKey=DERM%2F89343\" class=\"graphic graphic_picture graphicRef89343 \">picture 3A</a>). (See <a href=\"#H357895365\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Kasabach-Merritt phenomenon is characterized by profound thrombocytopenia and coagulopathy, due to platelet trapping in the tumor and consumption of fibrinogen. The presenting sign is a rapid enlargement of the tumor, which becomes tense, purpuric or ecchymotic, and painful (<a href=\"image.htm?imageKey=DERM%2F89100\" class=\"graphic graphic_picture graphicRef89100 \">picture 3C</a>). (See <a href=\"#H357895395\" class=\"local\">'Kasabach-Merritt phenomenon'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of tufted angioma or KHE is suspected in a child presenting with an atypical vascular lesion, red to purple in color, with ill-defined borders, most often located on the extremities or trunk (<a href=\"image.htm?imageKey=DERM%2F89065%7EDERM%2F89100%7EDERM%2F89264%7EDERM%2F89343\" class=\"graphic graphic_picture graphicRef89065 graphicRef89100 graphicRef89264 graphicRef89343 \">picture 3A, 3C-E</a>). A biopsy for histologic and immunohistochemical evaluation may be necessary to confirm the diagnosis. Laboratory findings of severe thrombocytopenia, hypofibrinogenemia, and elevated D-dimer suggest the diagnosis of Kasabach-Merritt phenomenon. (See <a href=\"#H357895402\" class=\"local\">'Diagnosis'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients <strong>without</strong> the Kasabach-Merritt phenomenon who have small or localized tumors, surgical excision is the treatment of choice. For nonresectable tufted angiomas, we suggest <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> 5 <span class=\"nowrap\">mg/kg</span> per day as first-line therapy. For nonresectable KHE, we suggest oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> or <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> 2 <span class=\"nowrap\">mg/kg</span> per day as first-line therapy and aspirin 2 to 5 <span class=\"nowrap\">mg/kg</span> per day as adjunctive therapy. Observation for spontaneous regression may be an option for lesions that are asymptomatic, do not cause functional compromise, and are not disfiguring. (See <a href=\"#H55701629\" class=\"local\">'Patients without Kasabach-Merritt phenomenon'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of patients <strong>with</strong> the Kasabach-Merritt phenomenon involves the treatment of the tumor responsible for the coagulopathy and hemostasis support. Surgical excision is the treatment of choice for small, localized tumors. For large, nonresectable tumors, we suggest intravenous <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a> <strong>and</strong> systemic corticosteroids or oral <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> with or without systemic corticosteroids (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Vincristine 0.05 <span class=\"nowrap\">mg/kg</span> is given intravenously once weekly; oral <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> 2 <span class=\"nowrap\">mg/kg</span> is given daily. Sirolimus is typically given at the dose of 0.8 <span class=\"nowrap\">mg/m<sup>2</sup></span> per dose with close monitoring of blood levels and supportive care; neonates and infants may need a lower dosing regimen due to physiologic differences in drug metabolism (<a href=\"image.htm?imageKey=DERM%2F115485\" class=\"graphic graphic_table graphicRef115485 \">table 1</a>). (See <a href=\"#H357895437\" class=\"local\">'Patients with Kasabach-Merritt phenomenon'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The need for hemostasis support, in particular for platelet infusion, should be based upon careful evaluation of the acuteness of the clinical presentation and the patient's needs (eg, active bleeding, upcoming surgery). (See <a href=\"#H357895446\" class=\"local\">'Hemostasis support'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/1\" class=\"nounderline abstract_t\">Cho KH, Kim SH, Park KC, et al. Angioblastoma (Nakagawa)--is it the same as tufted angioma? Clin Exp Dermatol 1991; 16:110.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/2\" class=\"nounderline abstract_t\">Jones EW, Orkin M. Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol 1989; 20:214.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/3\" class=\"nounderline abstract_t\">Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162:142.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/4\" class=\"nounderline abstract_t\">Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993; 17:321.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/5\" class=\"nounderline abstract_t\">Arai E, Kuramochi A, Tsuchida T, et al. Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol 2006; 33:492.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/6\" class=\"nounderline abstract_t\">Chu CY, Hsiao CH, Chiu HC. Transformation between Kaposiform hemangioendothelioma and tufted angioma. Dermatology 2003; 206:334.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/7\" class=\"nounderline abstract_t\">Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have &quot;true&quot; hemangiomas. J Pediatr 1997; 130:631.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/8\" class=\"nounderline abstract_t\">Rodriguez V, Lee A, Witman PM, Anderson PA. Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol 2009; 31:522.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/9\" class=\"nounderline abstract_t\">Ryan C, Price V, John P, et al. Kasabach-Merritt phenomenon: a single centre experience. Eur J Haematol 2010; 84:97.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/10\" class=\"nounderline abstract_t\">Lee B, Chiu M, Soriano T, Craft N. Adult-onset tufted angioma: a case report and review of the literature. Cutis 2006; 78:341.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/11\" class=\"nounderline abstract_t\">Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin North Am 2010; 57:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/12\" class=\"nounderline abstract_t\">Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28:559.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/13\" class=\"nounderline abstract_t\">Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol 2005; 18:1454.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/14\" class=\"nounderline abstract_t\">Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 2000; 13:180.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/15\" class=\"nounderline abstract_t\">Enjolras O, Soupre V, Picard A. Uncommon benign infantile vascular tumors. Adv Dermatol 2008; 24:105.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/16\" class=\"nounderline abstract_t\">Brasanac D, Janic D, Boricic I, et al. Retroperitoneal kaposiform hemangioendothelioma with tufted angioma-like features in an infant with Kasabach-Merritt syndrome. Pathol Int 2003; 53:627.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/17\" class=\"nounderline abstract_t\">Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000; 42:225.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/18\" class=\"nounderline abstract_t\">Herron MD, Coffin CM, Vanderhooft SL. Tufted angiomas: variability of the clinical morphology. Pediatr Dermatol 2002; 19:394.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/19\" class=\"nounderline abstract_t\">McAleer MA, Kirby B, Sheahan K, Collins P. An erythematous patch and plaque on the shoulder--quiz case. Acquired tufted angioma (TA). Arch Dermatol 2008; 144:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/20\" class=\"nounderline abstract_t\">Fujita H, Asahina A, Tamaki K. Extensive tufted angioma of the left arm in a 47-year-old woman. Clin Exp Dermatol 2009; 34:e216.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/21\" class=\"nounderline abstract_t\">Lam WY, Mac-Moune Lai F, Look CN, et al. Tufted angioma with complete regression. J Cutan Pathol 1994; 21:461.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/22\" class=\"nounderline abstract_t\">Miyamoto T, Mihara M, Mishima E, et al. Acquired tufted angioma showing spontaneous regression. Br J Dermatol 1992; 127:645.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/23\" class=\"nounderline abstract_t\">Wang L, Liu L, Wang G, Gao T. Congenital disseminated tufted angioma. J Cutan Pathol 2013; 40:405.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/24\" class=\"nounderline abstract_t\">Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC. Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol 2005; 58:214.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/25\" class=\"nounderline abstract_t\">Mulliken JB, Anupindi S, Ezekowitz RA, Mihm MC Jr. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13-2004. A newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med 2004; 350:1764.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/26\" class=\"nounderline abstract_t\">Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100:1377.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/27\" class=\"nounderline abstract_t\">Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005; 52:616.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/28\" class=\"nounderline abstract_t\">Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics 2016; 137:e20153257.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/29\" class=\"nounderline abstract_t\">Croteau SE, Kozakewich HP, Perez-Atayde AR, et al. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr 2014; 164:383.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/30\" class=\"nounderline abstract_t\">Safi F, Gupta A, Adams D, et al. Kaposiform lymphangiomatosis, a newly characterized vascular anomaly presenting with hemoptysis in an adult woman. Ann Am Thorac Soc 2014; 11:92.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/31\" class=\"nounderline abstract_t\">Fernandes VM, Fargo JH, Saini S, et al. Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder. Pediatr Blood Cancer 2015; 62:901.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/32\" class=\"nounderline abstract_t\">Wang Z, Li K, Yao W, et al. Successful treatment of kaposiform lymphangiomatosis with sirolimus. Pediatr Blood Cancer 2015; 62:1291.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/33\" class=\"nounderline abstract_t\">Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 2006; 48:63.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/34\" class=\"nounderline abstract_t\">Variend S, Bax NM, van Gorp J. Are infantile myofibromatosis, congenital fibrosarcoma and congenital haemangiopericytoma histogenetically related? Histopathology 1995; 26:57.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/35\" class=\"nounderline abstract_t\">Mentzel T, Calonje E, Nascimento AG, Fletcher CD. Infantile hemangiopericytoma versus infantile myofibromatosis. Study of a series suggesting a continuous spectrum of infantile myofibroblastic lesions. Am J Surg Pathol 1994; 18:922.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/36\" class=\"nounderline abstract_t\">Fernandez-Pineda I, Parida L, Jenkins JJ, et al. Childhood hemangiopericytoma: review of St Jude Children's Research Hospital. J Pediatr Hematol Oncol 2011; 33:356.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/37\" class=\"nounderline abstract_t\">Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 2. Australas J Dermatol 2009; 50:153.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/38\" class=\"nounderline abstract_t\">Grassia KL, Peterman CM, Iacobas I, et al. Clinical case series of pediatric hepatic angiosarcoma. Pediatr Blood Cancer 2017; 64.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/39\" class=\"nounderline abstract_t\">Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 1. Australas J Dermatol 2009; 50:77.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/40\" class=\"nounderline abstract_t\">Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995; 332:1181.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/41\" class=\"nounderline abstract_t\">Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/42\" class=\"nounderline abstract_t\">Drolet BA, Trenor CC 3rd, Brand&atilde;o LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 2013; 163:285.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/43\" class=\"nounderline abstract_t\">Browning J, Frieden I, Baselga E, et al. Congenital, self-regressing tufted angioma. Arch Dermatol 2006; 142:749.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/44\" class=\"nounderline abstract_t\">Ishikawa K, Hatano Y, Ichikawa H, et al. The spontaneous regression of tufted angioma. A case of regression after two recurrences and a review of 27 cases reported in the literature. Dermatology 2005; 210:346.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/45\" class=\"nounderline abstract_t\">Osio A, Fraitag S, Hadj-Rabia S, et al. Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature. Arch Dermatol 2010; 146:758.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/46\" class=\"nounderline abstract_t\">Javvaji S, Frieden IJ. Response of tufted angiomas to low-dose aspirin. Pediatr Dermatol 2013; 30:124.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/47\" class=\"nounderline abstract_t\">Munn SE, Jackson JE, Jones RR. Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature. Clin Exp Dermatol 1994; 19:511.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/48\" class=\"nounderline abstract_t\">Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/49\" class=\"nounderline abstract_t\">Chiu YE, Drolet BA, Blei F, et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012; 59:934.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/50\" class=\"nounderline abstract_t\">Wang Z, Li K, Dong K, et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2014; 61:1518.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/51\" class=\"nounderline abstract_t\">San Miguel FL, Spurbeck W, Budding C, Horton J. Kaposiform hemangioendothelioma: a rare cause of spontaneous hemothorax in infancy. Review of the literature. J Pediatr Surg 2008; 43:e37.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/52\" class=\"nounderline abstract_t\">Janic D, Brasanac D, Krstovski N, et al. The use of recombinant activated factor VII during major surgery in a child with Kasabach-Merritt syndrome. Paediatr Anaesth 2009; 19:177.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/53\" class=\"nounderline abstract_t\">Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J 2008; 1:9.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/54\" class=\"nounderline abstract_t\">Drolet BA, Scott LA, Esterly NB, Gosain AK. Early surgical intervention in a patient with Kasabach-Merritt phenomenon. J Pediatr 2001; 138:756.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/55\" class=\"nounderline abstract_t\">Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol 2012; 17:512.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/56\" class=\"nounderline abstract_t\">Blei F, Karp N, Rofsky N, et al. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol 1998; 15:295.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/57\" class=\"nounderline abstract_t\">Blatt J, Stavas J, Moats-Staats B, et al. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55:1396.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/58\" class=\"nounderline abstract_t\">Wang Z, Li K, Dong K, et al. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 2015; 37:72.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/59\" class=\"nounderline abstract_t\">Jahnel J, Lackner H, Reiterer F, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Klin Padiatr 2012; 224:395.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/60\" class=\"nounderline abstract_t\">Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 2015; 174:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/61\" class=\"nounderline abstract_t\">Uno T, Ito S, Nakazawa A, et al. Successful treatment of Kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer 2015; 62:536.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/62\" class=\"nounderline abstract_t\">Kai L, Wang Z, Yao W, et al. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol 2014; 140:471.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/63\" class=\"nounderline abstract_t\">Carrington PR. Truncal location of hemangioendotheliomas may indicate potentially more serious involvement with resulting Kasabach-Merritt syndrome than size determinant alone. J Am Acad Dermatol 2006; 54:922.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/64\" class=\"nounderline abstract_t\">Iacobas I, Simon ML, Amir T, et al. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms. Clin Imaging 2015; 39:529.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/65\" class=\"nounderline abstract_t\">Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990; 85:491.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/66\" class=\"nounderline abstract_t\">Shin HY, Ryu KH, Ahn HS. Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome. Pediatr Int 2000; 42:620.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/67\" class=\"nounderline abstract_t\">Ozsoylu S. High-dose intravenous methylprednisolone for Kasabach-Merritt syndrome. Am J Hematol 1989; 31:219.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/68\" class=\"nounderline abstract_t\">Ozsoylu S. Megadose methylprednisolone for Kasabach-Merritt syndrome. Pediatr Hematol Oncol 1993; 10:197.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/69\" class=\"nounderline abstract_t\">Ozsoylu S. Megadose methylprednisolone for Kasabach-Merritt syndrome. Eur J Pediatr 1996; 155:149.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/70\" class=\"nounderline abstract_t\">Ozsoylu S. Megadose methylprednisolone for Kasabach-Merritt syndrome. Pediatr Hematol Oncol 1999; 16:373.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/71\" class=\"nounderline abstract_t\">Ozsoylu S. About the treatment of Kasabach-Merritt syndrome. Pediatr Hematol Oncol 2000; 17:727.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/72\" class=\"nounderline abstract_t\">Ozsoylu S. Megadose methylprednisolone for Kasabach-Merritt syndrome. Eur J Pediatr 2003; 162:562; author reply 563.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/73\" class=\"nounderline abstract_t\">Ozsoylu S, Irken G, G&uuml;rgey A. High dose intravenous methylprednisolone for Kassabach-Merritt syndrome. Eur J Pediatr 1989; 148:403.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/74\" class=\"nounderline abstract_t\">Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24:459.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/75\" class=\"nounderline abstract_t\">Wang Z, Li K, Yao W, et al. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer 2015; 62:577.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/76\" class=\"nounderline abstract_t\">Barabash-Neila R, Garc&iacute;a-Rodr&iacute;guez E, Bernabeu-Wittel J, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine. Indian J Pediatr 2012; 79:1386.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/77\" class=\"nounderline abstract_t\">L&oacute;pez V, Mart&iacute; N, Pereda C, et al. Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine. Pediatr Dermatol 2009; 26:365.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/78\" class=\"nounderline abstract_t\">Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2013; 60:1478.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/79\" class=\"nounderline abstract_t\">Nadal M, Giraudeau B, Tavernier E, et al. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review. Acta Derm Venereol 2016; 96:448.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/80\" class=\"nounderline abstract_t\">Wang H, Duan Y, Gao Y, Guo X. Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients. Pediatr Dermatol 2017; 34:261.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/81\" class=\"nounderline abstract_t\">Boccara O, Puzenat E, Proust S, et al. The effects of sirolimus on Kasabach-Merritt phenomenon coagulopathy. Br J Dermatol 2018; 178:e114.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/82\" class=\"nounderline abstract_t\">Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer 2017; 141:848.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/83\" class=\"nounderline abstract_t\">Tasani M, Ancliff P, Glover M. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma. Br J Dermatol 2017; 177:e344.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/84\" class=\"nounderline abstract_t\">Mizuno T, Emoto C, Fukuda T, et al. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci 2017; 109S:S124.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/85\" class=\"nounderline abstract_t\">Mizuno T, Fukuda T, Emoto C, et al. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer 2017; 64.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/86\" class=\"nounderline abstract_t\">Castello MA, Ragni G, Antimi A, et al. Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Med Pediatr Oncol 1997; 28:213.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/87\" class=\"nounderline abstract_t\">Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997; 19:237.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/88\" class=\"nounderline abstract_t\">Deb G. Kaposiform hemangioendothelioma and therapy with interferon-alpha. Med Pediatr Oncol 2003; 41:593.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/89\" class=\"nounderline abstract_t\">Deb G, Jenkner A, De Sio L, et al. Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. Med Pediatr Oncol 1997; 28:358.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/90\" class=\"nounderline abstract_t\">Ettlinger JJ, Fleming PJ, Joffe HS, Kennedy CT. Cavernous haemangioma with Kasabach-Merritt syndrome: treatment with alpha-interferon. J R Soc Med 1996; 89:55P.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/91\" class=\"nounderline abstract_t\">Harper L, Michel JL, Enjolras O, et al. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon. Eur J Pediatr Surg 2006; 16:369.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/92\" class=\"nounderline abstract_t\">Hartman KR, Moncur JT, Minniti CP, Creamer KM. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon. J Pediatr Hematol Oncol 2009; 31:690.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/93\" class=\"nounderline abstract_t\">Klein C, Hauser M, Hadorn HB. Interferon alpha-2a therapy of consumptive coagulopathy in Kasabach-Merritt syndrome. Eur J Pediatr 1992; 151:919.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/94\" class=\"nounderline abstract_t\">Nako Y, Fukushima N, Igarashi T, et al. Successful interferon therapy in a neonate with life-threatening Kasabach-Merritt syndrome. J Perinatol 1997; 17:244.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/95\" class=\"nounderline abstract_t\">Yasui N, Koh K, Kato M, et al. Kasabach-Merritt phenomenon: a report of 11 cases from a single institution. J Pediatr Hematol Oncol 2013; 35:554.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/96\" class=\"nounderline abstract_t\">Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004; 114:1231.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/97\" class=\"nounderline abstract_t\">Fuchimoto Y, Morikawa N, Kuroda T, et al. Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies. Pediatr Int 2012; 54:285.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/98\" class=\"nounderline abstract_t\">Hauer J, Graubner U, Konstantopoulos N, et al. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer 2007; 49:852.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/99\" class=\"nounderline abstract_t\">Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol 1998; 20:567.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/100\" class=\"nounderline abstract_t\">Dresse MF, David M, Hume H, et al. Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 1991; 8:329.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/101\" class=\"nounderline abstract_t\">Hanna BD, Bernstein M. Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. Am J Pediatr Hematol Oncol 1989; 11:191.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/102\" class=\"nounderline abstract_t\">Ortel TL, Onorato JJ, Bedrosian CL, Kaufman RE. Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome. Am J Hematol 1988; 29:44.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/103\" class=\"nounderline abstract_t\">Shulkin BL, Argenta LC, Cho KJ, Castle VP. Kasabach-Merritt syndrome: treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy. J Pediatr 1990; 117:746.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/104\" class=\"nounderline abstract_t\">Garcia-Monaco R, Giachetti A, Peralta O, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns. J Vasc Interv Radiol 2012; 23:417.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/105\" class=\"nounderline abstract_t\">Hosono S, Ohno T, Kimoto H, et al. Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report. J Perinat Med 1999; 27:399.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/106\" class=\"nounderline abstract_t\">Zhou SY, Li HB, Mao YM, et al. Successful treatment of Kasabach-Merritt syndrome with transarterial embolization and corticosteroids. J Pediatr Surg 2013; 48:673.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/107\" class=\"nounderline abstract_t\">Atahan IL, Cengiz M, Ozyar E, G&uuml;rkaynak M. Radiotherapy in the management of Kasabach-Merritt syndrome: a case report. Pediatr Hematol Oncol 2001; 18:471.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/108\" class=\"nounderline abstract_t\">Hesselmann S, Micke O, Marquardt T, et al. Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol 2002; 75:180.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/109\" class=\"nounderline abstract_t\">Kwok-Williams M, Perez Z, Squire R, et al. Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome. Pediatr Blood Cancer 2007; 49:739.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/110\" class=\"nounderline abstract_t\">Leong E, Bydder S. Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome. J Med Imaging Radiat Oncol 2009; 53:87.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/111\" class=\"nounderline abstract_t\">Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys 1997; 39:467.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/112\" class=\"nounderline abstract_t\">Malhotra Y, Yang CS, McNamara J, Antaya RJ. Congenital kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon successfully treated with low-dose radiation therapy. Pediatr Dermatol 2014; 31:595.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/113\" class=\"nounderline abstract_t\">Boccara O, Fraitag S, Lasne D, et al. Kaposiform Haemangioendothelioma-spectrum Lesions with Kasabach-Merritt Phenomenon: Retrospective Analysis and Long-term Outcome. Acta Derm Venereol 2016; 96:77.</a></li><li><a href=\"https://www.uptodate.com/contents/tufted-angioma-kaposiform-hemangioendothelioma-and-the-kasabach-merritt-phenomenon/abstract/114\" class=\"nounderline abstract_t\">Schaefer BA, Wang D, Merrow AC, et al. Long-term outcome for kaposiform hemangioendothelioma: A report of two cases. Pediatr Blood Cancer 2017; 64:284.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 86314 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H357895488\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H357895344\" id=\"outline-link-H357895344\">INTRODUCTION</a></li><li><a href=\"#H357895351\" id=\"outline-link-H357895351\">EPIDEMIOLOGY</a></li><li><a href=\"#H357895358\" id=\"outline-link-H357895358\">PATHOGENESIS</a></li><li><a href=\"#H1841338\" id=\"outline-link-H1841338\">HISTOPATHOLOGY</a></li><li><a href=\"#H357895365\" id=\"outline-link-H357895365\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H357895374\" id=\"outline-link-H357895374\">Tufted angioma</a></li><li><a href=\"#H357895381\" id=\"outline-link-H357895381\">Kaposiform hemangioendothelioma</a></li><li><a href=\"#H357895395\" id=\"outline-link-H357895395\">Kasabach-Merritt phenomenon</a></li></ul></li><li><a href=\"#H357895402\" id=\"outline-link-H357895402\">DIAGNOSIS</a><ul><li><a href=\"#H26920701\" id=\"outline-link-H26920701\">Clinical examination</a></li><li><a href=\"#H26920734\" id=\"outline-link-H26920734\">Biopsy</a></li><li><a href=\"#H1841272\" id=\"outline-link-H1841272\">Laboratory evaluation</a></li><li><a href=\"#H357895409\" id=\"outline-link-H357895409\">Imaging studies</a></li></ul></li><li><a href=\"#H357895423\" id=\"outline-link-H357895423\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H357895430\" id=\"outline-link-H357895430\">MANAGEMENT</a><ul><li><a href=\"#H55701629\" id=\"outline-link-H55701629\">Patients without Kasabach-Merritt phenomenon</a></li><li><a href=\"#H357895437\" id=\"outline-link-H357895437\">Patients with Kasabach-Merritt phenomenon</a><ul><li><a href=\"#H357895446\" id=\"outline-link-H357895446\">- Hemostasis support</a></li><li><a href=\"#H357895453\" id=\"outline-link-H357895453\">- Surgical treatment</a></li><li><a href=\"#H357895474\" id=\"outline-link-H357895474\">- Pharmacologic therapy</a><ul><li><a href=\"#H4473191\" id=\"outline-link-H4473191\">Systemic corticosteroids</a></li><li><a href=\"#H4473187\" id=\"outline-link-H4473187\">Vincristine</a></li><li><a href=\"#H333840970\" id=\"outline-link-H333840970\">Sirolimus</a></li><li><a href=\"#H2081252668\" id=\"outline-link-H2081252668\">Interferon-alpha</a></li><li><a href=\"#H1655573282\" id=\"outline-link-H1655573282\">Multiagent chemotherapy</a></li><li><a href=\"#H2183472915\" id=\"outline-link-H2183472915\">Other therapies</a></li></ul></li><li><a href=\"#H1371846\" id=\"outline-link-H1371846\">- Embolization</a></li><li><a href=\"#H1371853\" id=\"outline-link-H1371853\">- Radiation therapy</a></li></ul></li><li><a href=\"#H19597040\" id=\"outline-link-H19597040\">Our approach</a></li></ul></li><li><a href=\"#H357895481\" id=\"outline-link-H357895481\">PROGNOSIS</a></li><li><a href=\"#H357895488\" id=\"outline-link-H357895488\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/86314|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/89833\" class=\"graphic graphic_picture\">- Tufted angioma histo</a></li><li><a href=\"image.htm?imageKey=DERM/89834\" class=\"graphic graphic_picture\">- KHE histo</a></li><li><a href=\"image.htm?imageKey=DERM/89065\" class=\"graphic graphic_picture\">- Tufted angioma</a></li><li><a href=\"image.htm?imageKey=DERM/89343\" class=\"graphic graphic_picture\">- Kaposiform hemangioendothelioma 2</a></li><li><a href=\"image.htm?imageKey=DERM/89260\" class=\"graphic graphic_picture\">- Kaposiform hemangioendothelioma 3</a></li><li><a href=\"image.htm?imageKey=DERM/89100\" class=\"graphic graphic_picture\">- Kaposiform hemangioendothelioma</a></li><li><a href=\"image.htm?imageKey=DERM/89264\" class=\"graphic graphic_picture\">- Kaposiform hemangioendothelioma leg</a></li><li><a href=\"image.htm?imageKey=PEDS/60004\" class=\"graphic graphic_picture\">- Superficial hemangioma</a></li><li><a href=\"image.htm?imageKey=PEDS/50388\" class=\"graphic graphic_picture\">- Deep hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/89197\" class=\"graphic graphic_picture\">- Hemangiopericytoma infant</a></li></ul></li><li><div id=\"DERM/86314|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/115485\" class=\"graphic graphic_table\">- Sirolimus starting dose in neonates and infants</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aids-related-kaposi-sarcoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma\" class=\"medical medical_review\">Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">Capillary malformations (port wine stains) and associated syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disseminated-intravascular-coagulation-in-infants-and-children\" class=\"medical medical_review\">Disseminated intravascular coagulation in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications\" class=\"medical medical_review\">Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hemangiomas-evaluation-and-diagnosis\" class=\"medical medical_review\">Infantile hemangiomas: Evaluation and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hemangiomas-management\" class=\"medical medical_review\">Infantile hemangiomas: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapidly-involuting-congenital-hemangioma-rich-and-noninvoluting-congenital-hemangioma-nich\" class=\"medical medical_review\">Rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=red-blood-cell-transfusion-in-infants-and-children-selection-of-blood-products\" class=\"medical medical_review\">Red blood cell transfusion in infants and children: Selection of blood products</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=skin-nodules-in-newborns-and-infants\" class=\"medical medical_review\">Skin nodules in newborns and infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-malformations\" class=\"medical medical_review\">Venous malformations</a></li></ul></div></div>","javascript":null}